patent.fyi
Applications  /  US 2026/0356976
United States Patent Application Publication

US 2026/0356976 A1

Published
Nov 12, 2026
Filed
Oct 9, 2024
Earliest date on the face
Oct 11, 2023
Classification
C07K 16/3092
First published here
Nov 20, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

No entries.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Reference reagent for tissue assay calibration

An anti-MUC1* antibody carries a cytotoxic small molecule through a covalent linker and serves as a reference reagent for an ex vivo tissue assay. A multiwell plate holds MUC1*-positive tumor organoids and matched organoids lacking MUC1*. Each set receives a dilution series of the conjugate, and a plate reader measures viability to establish the assay response range.

Component substitution

Antigen binding fragment replaces intact antibody

A recombinant antigen-binding fragment retains the anti-MUC1* variable domains and carries a single engineered cysteine near the heavy-chain terminus. A maleimide group on the linker couples a cytotoxic small molecule to that cysteine through a thioether bond. The resulting conjugate binds MUC1* through its single antigen-binding site.

Noncleavable thioether linker for lysosomal processing

A noncleavable maleimidocaproyl linker replaces a linker that releases its payload by cleavage. The linker joins a cysteine on the anti-MUC1* antibody to a cytotoxic small molecule such as monomethyl auristatin F. After a target cell internalizes the conjugate, lysosomal degradation of the antibody produces a metabolite that retains the cysteine and linker attached to the drug.

Parameter or scale variation

Two defined drug loading levels

Two versions of an anti-MUC1* antibody carry either one or two engineered conjugation sites per heavy chain. Each site couples to one linker-bound cytotoxic small molecule, yielding target drug-to-antibody ratios of 2 and 4. Intact mass spectrometry measures the loading distribution in each purified preparation.

Combination with existing systems

Conjugation with membrane based purification

A stirred vessel holds an anti-MUC1* antibody during coupling to a linker-bound cytotoxic small molecule. The vessel connects to a recirculating tangential-flow filtration system that retains the antibody conjugate and passes low-molecular-weight residual reagents into the permeate. Diafiltration exchanges the retained conjugate into the formulation buffer before collection.

Automated or data-driven variant

Automated measurement of drug loading

An autosampler injects aliquots of an anti-MUC1* antibody conjugation mixture into a hydrophobic interaction chromatography system. Software assigns resolved peaks to drug-loading states using a characterized reference mixture and calculates the average drug-to-antibody ratio from response-corrected peak areas. The software records the measured ratio and the fraction of unconjugated antibody for each aliquot.

Cite aspatent.fyi, US 2026/0356976 A1, claim 1, first published 2026-11-20T08:53:13-05:00, https://patent.fyi/US20260356976/, SHA-256 a3c0b6f162a320ce2fe852aa5b4acdf1da01410273aa6703a46a17699d9c87f8
First published
Permanent addresshttps://patent.fyi/US20260356976/
Content fingerprint (SHA-256)a3c0b6f162a320ce2fe852aa5b4acdf1da01410273aa6703a46a17699d9c87f8
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi